Bioanalytical approach to accelerate development efforts in the identification of compounds that can treat chlorine or sulfur mustard injuries
Laurus Labs Limited has reported consolidated financial results for the period ended September 30, 2021
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
The issue will consist of the issuance of fresh equity shares worth up to Rs 331.60 crore and an offer for sale (OFS) of Rs 500 crore by promoters and existing shareholders
The company plans to submit the IND application by the end of 2021
As part of this strategic partnership, LTI with its digital, technical and life sciences domain capabilities, will help accelerate joint go-to-market pursuits and faster deployment for Clinpal Adopters
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
Research collaboration covers multiple antibody research programs
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The drug is also intended for the treatment of glioblastoma multiforme
Subscribe To Our Newsletter & Stay Updated
